Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Weight loss “wonder drug” Wegovy will cost Irish users around €220 a month as it is not currently availably under either the ...
The issuer is solely responsible for the content of this announcement.
Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors ...
Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...
Less than five years on from when Novo Nordisk's semaglutide drug received FDA approval for weight loss (Wegovy), the Danish pharmaceutical company has announced it will seek regulatory approval ...
As China embarks on its three-year "weight management" campaign, Novo Nordisk has stepped forward with its powerful tools to ...
Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time ...
German software company SAP has overtaken Novo Nordisk, a Danish healthcare company behind weight loss drug Ozempic, as Europe's largest company by market capitalization.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback